Bibliographic Details
| Title: |
In Silico Mining of Natural Products Atlas (NPAtlas) Database for Identifying Effective Bcl-2 Inhibitors: Molecular Docking, Molecular Dynamics, and Pharmacokinetics Characteristics |
| Authors: |
Nahlah Makki Almansour, Khaled S. Allemailem, Abeer Abas Abd El Aty, Ekram Ismail Fagiree Ismail, Mahmoud A. A. Ibrahim |
| Source: |
Molecules, Vol 28, Iss 2, p 783 (2023) |
| Publisher Information: |
MDPI AG, 2023. |
| Publication Year: |
2023 |
| Collection: |
LCC:Organic chemistry |
| Subject Terms: |
Bcl-2 protein, cancer disease, MD simulations, molecular docking, pharmacokinetics features, Organic chemistry, QD241-441 |
| More Details: |
The Bcl-2 protein has a vital function in controlling the programmed cell doom of mitochondria. If programmed cell death signals are obstructed, an imbalance between cell survival and death will occur, which is a significant reason for cancer. Therefore, the Bcl-2 protein was identified as a possible therapeutic target for carcinoma treatment. Herein, the Natural Products Atlas (NPAtlas) compounds were virtually screened, seeking potent inhibitors towards the Bcl-2 protein. The performance of AutoDock Vina software to predict the docking score and pose of the investigated compounds was first validated according to the available experimental data. Based on the validated AutoDock Vina parameters, the NPAtlas database was filtered against the Bcl-2 protein. The natural compounds with docking scores less than that of the venetoclax (calc. −10.6 kcal/mol) were submitted to MD simulations, followed by MM-GBSA binding energy calculations. According to MM-GBSA//200 ns MD simulations, saquayamycin F (NPA002200) demonstrated promising binding affinity with a ΔGbinding value of −53.9 kcal/mol towards the Bcl-2 protein when compared to venetoclax (ΔGbinding = −50.6 kcal/mol). The energetical and structural analyses showed a great constancy of the saquayamycin F inside the Bcl-2 protein active site. Moreover, the ADMET and drug-likeness features of the saquayamycin F were anticipated, indicating its good oral bioavailability. According to in silico computations, saquayamycin F is proposed to be used as a therapeutic agent against the wild-type Bcl-2 protein and warrants further experimental assays. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
1420-3049 |
| Relation: |
https://www.mdpi.com/1420-3049/28/2/783; https://doaj.org/toc/1420-3049 |
| DOI: |
10.3390/molecules28020783 |
| Access URL: |
https://doaj.org/article/7734c3d2d60542989d5adc8253457ab2 |
| Accession Number: |
edsdoj.7734c3d2d60542989d5adc8253457ab2 |
| Database: |
Directory of Open Access Journals |
|
Full text is not displayed to guests. |
Login for full access.
|
